CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Athira’s safety and efficacy trial, geared for 75 patients, will run with a smaller-than-planned 28 patient study population. The trial is for the small molecule fosgonimeton, an activator of the HGF/MET pathway, postulated to offer neuroprotective effects to improve brain function in patients with Parkinson’s dementia.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
